Figure 1
Figure 1. PPM1D mutant cells have a competitive advantage under the selective pressure of chemotherapy (cytarabine) treatment.

PPM1D mutant cells have a competitive advantage under the selective pressure of chemotherapy (cytarabine) treatment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal